Iridex to Report Third Quarter 2022 Financial Results on November 10, 2022
Iridex Corporation (NASDAQ: IRIX) will release its third-quarter 2022 financial results on November 10, 2022, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Iridex Corporation (NASDAQ: IRIX) will release its third-quarter 2022 financial results on November 10, 2022, after market close. A conference call with management will follow at 2:00 p.m. PT / 5:00 p.m. ET. Investors can access the live and recorded webcast on the Company’s website.
Iridex specializes in innovative ophthalmic laser-based medical products, primarily treating glaucoma and retinal diseases. Their products are distributed in the U.S., Germany, and over 100 other countries.
Positive
- The upcoming financial results release date indicates ongoing transparency with investors.
Negative
- None.
Details
News Market Reaction – IRIX
The recorded move for IRIX in the trading session of this news was -0.44%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter of 2022 after the close of trading on Thursday, November 10, 2022. The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET.
Investors interested in listening to the conference call may do so by accessing the live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at: www.iridex.com.
About Iridex
Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit www.iridex.com.
Investor Relations Contact:
Philip Taylor
investors@iridex.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.